Laureate Pharma and Selexis to expand marketing agreement
Laureate Pharma, a US-based biopharmaceutical contract manufacturing organisation and Selexis, a Swiss contract developer of high performance production cell lines, will continue their collaboration via a joint-marketing agreement. This expanded relationship will provide streamlined access to complementary contract services, said Laureate.
Laureate Pharma, a US-based biopharmaceutical contract manufacturing organisation and Selexis, a Swiss contract developer of high performance production cell lines, will continue their collaboration via a joint-marketing agreement. This expanded relationship will provide streamlined access to complementary contract services, said Laureate.
The two companies say they are able to generate productive, stable mammalian cells producing gram quantities of recombinant protein materials in eight weeks, post transfection. In addition, they can develop cGMP compliant manufacturing processes for streamlined production of clinical grade material.
"Combining the Selexis approach to cell line development with our strong track record of cGMP manufacturing provides a very compelling value proposition for clients looking to outsource biopharmaceutical manufacturing," said Robert Broeze, president and ceo of Laureate Pharma, which is based in Princeton, NJ.
"Including Laureate in our network of manufacturing partners is of great benefit to our clients seeking a US-based manufacturer with a long history of successful cGMP compliant manufacturing," added Igor Fisch, president and ceo of Selexis.